1334-P: Prognostic Implications of Diabetic Ketoacidosis on Long-Term Mortality and Diabetes-Related Complications

Introduction 0.001], major adverse cardiovascular events (HR 2.05, 95% CI 1.34-3.13, p0.001), and all advanced microvascular and acute complications compared to no DKA after diabetes diagnosis. Most associations were significant even after adjustment for covariates. The cumulative incidence and hazard estimates for someone exposed to DKA compared to unexposed were greater for mortality (6.0% vs. 1.3%), major adverse cardiovascular events (12.3% vs. 6.5%), advanced neuropathy (23.1% vs. 14.4%), advanced nephropathy (6.8% vs. 2.2%), advanced retinopathy (51.9% vs. 43.7%), severe hypoglycemia (6 events vs. 5 events), and recurrent DKA (1 event vs. 0 events). Conclusions: DKA is a prognostic marker for diabetes complications, including excess mortality. Intensified clinical interventions, such as enhanced self-management education, glycemic control, and cardiovascular prevention strategies may be warranted following the diagnosis of DKA. Disclosure D.R. Budhram: None. P. Bapat: None. A.M.K. Bakhsh: None. M.I. Abuabat: None. N. Verhoeff: None. D. Mumford: None. A. Orszag: None. A.B. Jain: Advisory Panel; Abbott. Speaker's Bureau; Abbott. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Advisory Panel; Amgen Inc. Speaker's Bureau; Amgen Inc., AstraZeneca. Advisory Panel; AstraZeneca. Speaker's Bureau; Care to Know, CCRN, Connected in Motion, CPD Network, Dexcom, Diabetes Canada, Eli Lilly, GSK, HLS Therapeutics, Janssen, Master Clinician Alliance, MDBriefcase, Merck, Medtronic, Moderna, Novartis, N. Advisory Panel; Bausch Healthcare, Bayer,, Dexcom, Eli Lilly, Gilead Sciences, GSK, HLS Therapeutics, Insulet, Janssen, Medtronic, Novo Nordisk, Partners in Progressive Medical Education, Pfizer, PocketPills, Roche,. M. Fralick: Consultant; singal1, proofdx. A. Weisman: None. L. Lovblom: None. B.A. Perkins: Advisory Panel; Abbott. Other Relationship; Novo Nordisk. Advisory Panel; Insulet Corporation, Nephris. Other Relationship; Medtronic. Advisory Panel; Sanofi, Vertex Pharmaceuticals Incorporated, Dexcom, Inc. Funding Diabetes Canada (Operating Grant OG-3-21-5572-BP)